$BMY

25 stories mentioning BMYUpdated 9h ago

Every FINWIRES story that references BMY, newest first.

Bristol-Myers Squibb to Stay Range-Bound Until H2 Data, RBC Says

Bristol-Myers Squibb (BMY) Q1 results were solid but driven largely by legacy products rather than growth drivers, while the stock is expected to remain range-bound in the near term until more concrete data emerges in H2, RBC Capital Markets said.The brokerage said in a Thursday note that the about 5% rally in the stock reflected increasing pipeline confidence following the Q1 call, rather than the quarterly results themselves.RBC said it was encouraged by the growing attention on the often overlooked CELMoD franchise, which offers several potential opportunities that could support upside.The firm reiterated a sector perform rating with a price target of $60, saying further upside will depend on successful pipeline execution.Price: $58.65, Change: $-1.95, Percent Change: -3.21%

$BMY

Wire90d ago

Citigroup Adjusts Bristol-Myers Squibb Price Target to $66 From $64

Bristol-Myers Squibb Company (BMY) has an average rating of overweight and mean price target of $63.57, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $58.90, Change: $-1.69, Percent Change: -2.79%

$BMY

Wire90d ago

BMO Capital Adjusts Bristol-Myers Squibb Price Target to $60 From $55

$BMY

Research91d ago

Research Alert: Bmy Reports Strong Q1 Results Fueled By Growth Portfolio, Reaffirms Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BMY delivered solid Q1 2026 results with revenues of $11.5B (+3% Y/Y), $580M above the consensus. Meanwhile, non-GAAP EPS of $1.58 declined 12% Y/Y but beat the consensus by $0.16. Growth Portfolio demonstrated exceptional strength with 12% Y/Y expansion to $6.2B, now representing the majority of total sales versus the Legacy Portfolio at $5.3B (-6% Y/Y). We think the company's diversification strategy is showing clear progress, with standout performances from Camzyos ($314M, +97% Y/Y), Breyanzi ($411M, +56% Y/Y), and continued Eliquis resilience ($4.1B, +16% Y/Y). Management reaffirmed 2026 revenue guidance of $46.0B-$47.5B and non-GAAP EPS guidance of $6.05-$6.35, with performance trending toward upper end of range. We believe the Growth Portfolio momentum positions BMY well for future growth despite Legacy Portfolio headwinds from generic competition, particularly after Revlimid's sharp decline to $349M (-63% Y/Y).

$BMY

Wire111d ago

Bristol-Myers Squibb Poised for In-Line Q1 Amid One-Off Volatility, RBC Says

Bristol-Myers Squibb's (BMY) Q1 results are expected to come in line with consensus, but weaker oncology sales and one-off factors are likely to give way to volatility, RBC Capital Markets said Friday in a note.The investment firm said the quarter will be difficult to model due to volatility from destocking patterns, tough year-over-year comparisons, policy impacts and generic phasing dynamics.RBC said it estimates the company to report Q1 revenue of $10.75 billion and earnings of $1.42 per share. Analysts polled by FactSet expect $1.42 in non-GAAP EPS, $1.17 in GAAP EPS and $10.87 billion in revenue.Investor focus during the quarterly call will be on the company's upcoming trial results, particularly late-stage data for drug candidates milvexian and cobenfy, which are key to determining when Bristol-Myers returns to growth.Bristol-Myers will report Q1 results on April 30.RBC has a sector perform rating and price target of $60 on the stock.Price: $58.62, Change: $-0.85, Percent Change: -1.44%

$BMY

Showing 21-25 of 25

Track with the FINWIRES app suite

FolioX

Track BMY in your portfolio

WheelAI

Analyze BMY options with the wheel strategy

StockInsider

See market sentiment on BMY